News Center.
In the news:
AAPL.
CAT.
SVU.
BTU.
ACOM.
..
.
Stereotaxis Elects Euan S. Thomson, Ph.D., to Board of Directors
October 22, 2012 4:18 PM ET.
Share
0
TICKERS IN THIS ARTICLE.
NAME
LAST
CHNG
% CHNG
STXS
1.90
+0.67
+54.47
ST. LOUIS, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS +54.47%, news) today announced that Euan Thomson has been elected to its Board of Directors. The former President and CEO of Accuray Incorporated, Dr. Thomson, a medical physicist, has nearly 30 years experience in scientific research and strategic business leadership. He assumes the Board seat vacated by Christopher Alafi upon his retirement this year.
"Euan's unique blend of business acumen and medical innovation will be a tremendous asset as we continue to work toward market leadership and profitable growth through leading-edge, robotic solutions to important clinical challenges," said William Mills, Stereotaxis Board Chairman. "He has had outstanding success leading transformational change at Accuray and brings rich insight into securing global clinical adoption of groundbreaking technology."
Dr. Thomson holds a Master's in Radiation Physics and a Doctorate in Medical Physics from the University of London. Following his medical physics training, he devoted more than 15 years to research, teaching, clinical practice and administration with the United Kingdom Health Care System. During that time he worked as a consultant, advising companies and hospitals on scientific development, product marketing and management on an international scale. In 1999, Dr. Thomson moved to the U.S. to assume the reins at Photoelectron Corporation, a Boston-based company specializing in miniature x-ray technology for the medical and industrial markets.
Dr. Thomson was appointed President and CEO of Accuray, a medical capital equipment company, in 2002. During his 10-year tenure, he grew Accuray from a start-up to a public company with more than 1,000 employees, generating more than $400M in annual revenue. Dr. Thomson oversaw expansion of distribution channels to include more than 80 countries and development of the patent portfolio to approximately 300 US and foreign patents. Accuray built clinical programs that resulted in treatments to hundreds of thousands of patients worldwide and built an installed base exceeding 600 systems. In 2009, Dr. Thomson was recognized as Ernst and Young "Entrepreneur of the Year" in healthcare for Northern California. He currently serves as the Chair of the American Cancer Society's "CEO's Against Cancer" (California division) and is a Board member of the Hospice of the Valley. Dr. Thomson recently announced his resignation from Accuray, where it is anticipated he will continue to serve as a consultant.
"I'm excited to join an accomplished Board of Directors in providing strategic guidance to a company focused on transforming the world of interventional medicine," Dr. Thomson said of his appointment to the Stereotaxis Board. "Stereotaxis is poised for profitability and well positioned for growth in an expanding worldwide market. I look forward to being part of the future of an enterprising organization."
